Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adrenal cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    77 result(s) found for: Adrenal cancer. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2004-001125-20 Sponsor Protocol Number: FIRM-ACT Start Date*: 2004-07-26
    Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA
    Full Title: First International Randomized trial in Metastatic Adrenocortical Cancer Treatment FIRM-ACT Etoposide, Doxorubicin, Cisplatin and Mitotane vs. Streptozotocin and Mitotane
    Medical condition: Chemotherapy in patients with locally advanced or metastatic adrenocortical cancer in adults and children
    Disease: Version SOC Term Classification Code Term Level
    6.1 10001378 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001802-27 Sponsor Protocol Number: F002MH0218_1 Start Date*: 2019-04-16
    Sponsor Name:University Hospital Wuerzburg
    Full Title: A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma.
    Medical condition: Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10001353 Adrenal gland disorders HLGT
    20.0 10014698 - Endocrine disorders 10001341 Adrenal cortical hyperfunctions HLT
    20.0 10014698 - Endocrine disorders 10001376 Adrenal neoplasms HLT
    20.0 100000004864 10001378 Adrenal neoplasms malignant HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007262-38 Sponsor Protocol Number: ADIUVO Start Date*: 2008-03-12
    Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA
    Full Title: Efficacy of adjuvant mitotane treatment in prolonging disease-free survival in patients with adrenocortical cacinoma submitted to radical resection
    Medical condition: PATIENTS WITH ADRENOCORTICAL CARCINOMA SUBMITTED TO RARICAL SURGERY
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001388 Adrenocortical carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-001165-15 Sponsor Protocol Number: SIRAC-1 Start Date*: 2007-06-08
    Sponsor Name:University Hospital of Wuerzburg
    Full Title: Sunitinib in Refractory Adrenocortical-Carcinoma patients progressing after cytotoxic chemotherapy (SIRAC)
    Medical condition: Adrenocortical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001388 Adrenocortical carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012820-97 Sponsor Protocol Number: OSI-906-301 Start Date*: 2009-12-29
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma
    Medical condition: Adrenocortical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002632-99 Sponsor Protocol Number: ONC-NET-01 Start Date*: 2011-10-14
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: SUTNET Trial: Biological and Clinical Phase II study of Sunitinib in patients with unresectable and/or metastatic pheochromocytoma/paraganglioma
    Medical condition: Patients with unresectable and/or metastatic pheochromocytomas/paragangliomas
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001375 Adrenal neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001591-35 Sponsor Protocol Number: ASST-ONCO-CABAC2017 Start Date*: 2017-12-27
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Multicenter, prospective, non-randomized, phase II trial designed to evaluate the activity of Cabazitaxel in patients with advanced Adreno-Cortical- Carcinoma progressing after previous chemotherap...
    Medical condition: Histologically confirmed diagnosis of ACC Locally advanced or metastatic disease not amenable to radical surgery resection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061588 Adrenal neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000494-91 Sponsor Protocol Number: PEMBR-01 Start Date*: 2022-12-22
    Sponsor Name:Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, Państwowy Instytut Badawczy
    Full Title: A multicentre, open-label phase 2 study to evaluate the efficacy and safety of pembrolizumab in the treatment of advanced, progressive adrenocortical carcinoma.
    Medical condition: carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004530-38 Sponsor Protocol Number: ASSTBS-FARONCO-PESETA-20 Start Date*: 2022-05-30
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: PROSPECTIVE, PHASE II STUDY TO EVALUATE THE EFFICACY OF ADDITION OF PROGESTERONE TO STANDARD CHEMOTHERAPY ACCORDING TO EDP SCHEME PLUS MITOTANE IN PATIENTS WITH ADVANCED ADRENALCORTICAL (PESETA TRIAL)
    Medical condition: advanced/ metastatic patients with ACC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000945-29 Sponsor Protocol Number: ASSTBS-ONCO-ABACUS-16 Start Date*: 2016-06-16
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS)
    Medical condition: Cushing’s syndrome in patients with adrenocortical carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000580-90 Sponsor Protocol Number: ASSTBS-ONCO-ACACIA-18 Start Date*: 2018-06-20
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Multicenter randomized open-label phase III trial of Adjuvant Chemotherapy vs. observation or mitotane after primary surgical resection of localized
    Medical condition: localized Adrenocortical CarcInomA with high risk of recurrence
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004137-18 Sponsor Protocol Number: CO-ACT-001 Start Date*: 2007-10-19
    Sponsor Name:Collaborative group for Adrenocortical Carcinoma Therapy (COAT) [...]
    1. Collaborative group for Adrenocortical Carcinoma Therapy (COAT)
    2. University of Würzburg, Internat. study-Coordinator
    Full Title: First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
    Medical condition: chemotherapy with etoposide, doxorubicin and cisplatin plus mitotane (EDP/M) as first line treatment versus streptozotocin plus mitotane (Sz/M) as first line treatment in advanced and Metastatic Ad...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001388 Adrenocortical carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2020-005157-24 Sponsor Protocol Number: 75688 Start Date*: 2021-09-21
    Sponsor Name:UMC Utrecht
    Full Title: [18F]mFBG PET-CT imaging of pheochromocytoma
    Medical condition: Pheochromocytoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10034876 Pheochromocytoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003163-29 Sponsor Protocol Number: SNIPP Start Date*: 2012-06-08
    Sponsor Name:University Medical Center Groningen
    Full Title: SNIPP study - A investigator initiated phase II study of Sunitinib in patients with recurrent paraganglioma/pheochromocytoma
    Medical condition: Paraganglioma/pheochromocytoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034876 Pheochromocytoma LLT
    Population Age: Adults, Elderly Gender:
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002873-47 Sponsor Protocol Number: SOGUG2011-03 Start Date*: 2011-11-25
    Sponsor Name:Grupo Español de Oncología Genitourinaria (SOGUG)
    Full Title: PHASE II CLINICAL TRIAL OF DOVITINIB (TKI-258) IN FIRST-LINE METASTATIC OR LOCALLY ADVANCED NON-RESECTABLE ADRENOCORTICAL CARCINOMA
    Medical condition: Carcinoma adrenocortical metastásico o localmente avanzado no resecable, confirmado histológicamente.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003396-19 Sponsor Protocol Number: EOADR1-19 Start Date*: 2020-05-28
    Sponsor Name:Enterome
    Full Title: A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of patients with locally advanced or metastatic adr...
    Medical condition: - locally advanced or metastatic adrenocortical carcinoma (ACC) - malignant pheochromocytoma/paraganglioma (MPP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034876 Pheochromocytoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075444 Malignant paraganglioma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Ongoing) ES (Completed) DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004076-34 Sponsor Protocol Number: 7487-CL-0209 Start Date*: 2014-02-27
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A phase II open-label rollover study for subjects that have participated in an Astellas sponsored linsitinib trial
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003431-29 Sponsor Protocol Number: CBGG492A2216 Start Date*: 2014-05-27
    Sponsor Name:Novartis Farma S.p.A.
    Full Title: A multicenter medical safety follow-up study for patients with partial onset seizures who received more than 28 days of total exposure to BGG492 in studies CBGG492A2207 and/or CBGG492A2212.
    Medical condition: Testing for adrenal cortical adenomas in male and female patients Testing for uterine endometrial stromal sarcromas in all female patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005648-25 Sponsor Protocol Number: PHRC/07-03/RENNES Start Date*: 2008-01-31
    Sponsor Name:C.H.U. de RENNES
    Full Title: Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante: valeur pronostique et thérapeutique des altérations du gène VHL et de l’expression plasmatiq...
    Medical condition: Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001326 Adrenal carcinoma LLT
    9.1 10001327 Adrenal carcinoma NOS LLT
    9.1 10038395 Renal carcinoma LLT
    9.1 10038396 Renal carcinoma recurrent LLT
    9.1 10038397 Renal carcinoma stage I LLT
    9.1 10038398 Renal carcinoma stage II LLT
    9.1 10038399 Renal carcinoma stage III LLT
    9.1 10038400 Renal carcinoma stage IV LLT
    9.1 10050076 Metastatic renal carcinoma LLT
    9.1 10001326 Adrenal carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002951-39 Sponsor Protocol Number: CAAA601A32201 Start Date*: Information not available in EudraCT
    Sponsor Name:Advanced Accelerator Applications SA
    Full Title: A multicenter open-label study to evaluate safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheoc...
    Medical condition: somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034876 Pheochromocytoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073860 Paraganglioma LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Trial now transitioned) PT (Prematurely Ended) PL (Trial now transitioned) BE (Completed) IT (Completed) NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Nov 03 01:24:50 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA